ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 186 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $765 | -27.8% | 47,110 | -17.9% | 0.00% | -100.0% |
| Q1 2024 | $1,060 | -43.9% | 57,376 | -5.0% | 0.00% | 0.0% |
| Q4 2023 | $1,890 | +14.3% | 60,365 | -24.0% | 0.00% | 0.0% |
| Q3 2023 | $1,654 | +1869.0% | 79,388 | +1397.9% | 0.00% | – |
| Q4 2022 | $84 | -100.0% | 5,300 | -64.2% | 0.00% | – |
| Q3 2022 | $242,000 | +227.0% | 14,802 | +179.3% | 0.00% | – |
| Q2 2022 | $74,000 | -82.1% | 5,300 | -69.0% | 0.00% | – |
| Q1 2022 | $414,000 | -79.5% | 17,100 | -80.2% | 0.00% | -100.0% |
| Q4 2021 | $2,016,000 | +58.6% | 86,393 | +68.2% | 0.00% | +100.0% |
| Q3 2021 | $1,271,000 | +1.9% | 51,352 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $1,247,000 | -46.8% | 51,152 | -43.7% | 0.00% | -75.0% |
| Q1 2021 | $2,344,000 | – | 90,857 | +320.3% | 0.00% | – |
| Q4 2020 | $0 | – | 21,618 | -1.9% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 22,045 | +103.5% | 0.00% | -100.0% |
| Q1 2020 | $457,000 | -60.2% | 10,834 | -59.7% | 0.00% | -66.7% |
| Q4 2019 | $1,148,000 | -53.0% | 26,854 | -60.4% | 0.00% | -57.1% |
| Q3 2019 | $2,440,000 | +176.3% | 67,820 | +105.2% | 0.01% | +250.0% |
| Q2 2019 | $883,000 | -51.7% | 33,045 | -51.5% | 0.00% | -60.0% |
| Q1 2019 | $1,830,000 | +229.7% | 68,181 | +98.3% | 0.01% | +150.0% |
| Q4 2018 | $555,000 | -23.8% | 34,376 | -2.0% | 0.00% | 0.0% |
| Q3 2018 | $728,000 | +86.7% | 35,073 | +37.3% | 0.00% | 0.0% |
| Q2 2018 | $390,000 | +28.7% | 25,548 | +153.5% | 0.00% | -84.6% |
| Q4 2017 | $303,000 | -62.1% | 10,077 | -52.5% | 0.01% | -60.6% |
| Q3 2017 | $799,000 | -59.5% | 21,226 | -70.0% | 0.03% | -61.6% |
| Q2 2017 | $1,971,000 | +25.5% | 70,683 | +54.7% | 0.09% | +26.5% |
| Q1 2017 | $1,570,000 | +1265.2% | 45,691 | +1040.0% | 0.07% | +871.4% |
| Q4 2016 | $115,000 | -83.8% | 4,008 | -82.0% | 0.01% | -85.4% |
| Q3 2016 | $709,000 | -9.2% | 22,315 | -7.4% | 0.05% | -7.7% |
| Q2 2016 | $781,000 | +984.7% | 24,090 | +828.0% | 0.05% | +766.7% |
| Q1 2016 | $72,000 | -76.3% | 2,596 | -69.6% | 0.01% | -75.0% |
| Q4 2015 | $304,000 | +360.6% | 8,543 | +321.7% | 0.02% | +380.0% |
| Q3 2015 | $66,000 | +57.1% | 2,026 | +98.2% | 0.01% | +25.0% |
| Q2 2015 | $42,000 | – | 1,022 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 916,353 | $17,245,763 | 6.59% |
| Baker Brothers Advisors | 41,938,486 | $789,282,307 | 4.29% |
| Palo Alto Investors LP | 2,405,793 | $45,277,024 | 3.75% |
| Birchview Capital, LP | 249,400 | $4,694 | 3.68% |
| EcoR1 Capital, LLC | 5,991,479 | $112,759,635 | 3.63% |
| RTW INVESTMENTS, LP | 8,242,864 | $155,130,700 | 3.23% |
| EMERALD ADVISERS, LLC | 1,496,560 | $28,165,259 | 1.35% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,207,302 | $22,721,424 | 1.34% |
| Frazier Life Sciences Management, L.P. | 857,338 | $16,135,101 | 1.17% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $4,060,800 | 1.13% |